- Home
- AGIO vs EVV Comparison
AGIO vs EVV Comparison
Compare AGIO & EVV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- EVV
- Stock Information
- Founded
- AGIO 2007
- EVV 2003
- Country
- AGIO United States
- EVV United States
- Employees
- AGIO N/A
- EVV N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- EVV Finance/Investors Services
- Sector
- AGIO Health Care
- EVV Finance
- Exchange
- AGIO Nasdaq
- EVV Nasdaq
- Market Cap
- AGIO 1.4B
- EVV 1.2B
- IPO Year
- AGIO 2013
- EVV N/A
- Fundamental
- Price
- AGIO $39.05
- EVV $10.19
- Analyst Decision
- AGIO Buy
- EVV
- Analyst Count
- AGIO 6
- EVV 0
- Target Price
- AGIO $58.60
- EVV N/A
- AVG Volume (30 Days)
- AGIO 602.7K
- EVV 323.7K
- Earning Date
- AGIO 07-31-2025
- EVV 01-01-0001
- Dividend Yield
- AGIO N/A
- EVV 9.66%
- EPS Growth
- AGIO N/A
- EVV N/A
- EPS
- AGIO 11.45
- EVV N/A
- Revenue
- AGIO $37,035,000.00
- EVV N/A
- Revenue This Year
- AGIO $22.30
- EVV N/A
- Revenue Next Year
- AGIO $219.19
- EVV N/A
- P/E Ratio
- AGIO $3.45
- EVV N/A
- Revenue Growth
- AGIO 25.96
- EVV N/A
- 52 Week Low
- AGIO $23.42
- EVV $8.52
- 52 Week High
- AGIO $62.58
- EVV $10.07
- Technical
- Relative Strength Index (RSI)
- AGIO 70.00
- EVV 53.55
- Support Level
- AGIO $34.60
- EVV $10.20
- Resistance Level
- AGIO $40.06
- EVV $10.34
- Average True Range (ATR)
- AGIO 1.49
- EVV 0.08
- MACD
- AGIO 0.43
- EVV -0.00
- Stochastic Oscillator
- AGIO 86.59
- EVV 50.33
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About EVV Eaton Vance Limited Duration Income Fund of Beneficial Interest
Eaton Vance Ltd Duration Income Fund is a diversified closed-end management investment company. The company's investment objective is to provide a high level of current income. The Fund also seeks capital appreciation. The Fund invests predominantly in Senior Floating-Rate Loans, Debt Obligations, Equity Securities, Derivatives as well as Foreign Securities and Currencies. The Fund invests in various industries, including aerospace and defense, automotive, building and development, healthcare, and leisure, among others.